Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

Michael Bogart1 U.S. Value Evidence and Outcomes, R&D U.S., GSK, Research Triangle Park, Durham, NC, USAView further author information

Guillaume Germain2 Groupe d’Analyse, Ltée, Montréal, QC, CanadaView further author information

François Laliberté2 Groupe d’Analyse, Ltée, Montréal, QC, CanadaView further author information

Malena Mahendran2 Groupe d’Analyse, Ltée, Montréal, QC, CanadaView further author information

Mei Sheng Duh3 Analysis Group, Inc., Boston, MA, USA

https://orcid.org/0000-0001-5035-6687 View further author information

Kristi DiRocco4 U.S. Medical Affairs, GSK, Collegeville, PA, USACorrespondence[email protected]
View further author information

Stephen G Noorduyn5 Global Value Evidence and Outcomes, GSK, Mississauga, ON, Canada;6 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CanadaView further author information

Rosirene Paczkowski7 Value Evidence and Outcomes, GSK, Collegeville, PA, USAView further author information

Ronald Balkissoon8 National Jewish Health, Denver, CO, USAView further author information

show all

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date